Preventing recurrence of lung cancer, preventing recurrence after lung cancer surgery, how to prevent recurrence of lung cancer, how to prevent recurrence of lung cancer.
Kansarka sambabaha ayaa ah sababta ugu badan ee dhimashada kansarka la xiriirta adduunka oo dhan. Bukaannada goor hore (marxaladda I iyo II) kansarka sambabka unugyada aan-yareyn (NSCLC) iyo bukaanno qaarkood oo ku habboon deegaanka oo heer sare ah (marxaladda IIIA) oo aan ahayn kansarka unugyada unugyada yar yar, dhammaystirka qalliinka dhammaystiran ee nabarrada burooyinka ayaa ah habka daaweynta ugu fiican. In kasta oo horumar laga sameeyay baaritaanka hore iyo daaweynta oo si wax ku ool ah u wanaajiyay heerarka badbaadada, soo noqoshada qalliinka ka dib weli waa arrin muhiim ah.
After surgical resection, 30% -75% of kansarka sanbabada patients will relapse, including about 15% of patients with stage I lung cancer. Most recurrent tumors occur in distant lesions, and more than 80% of recurrent lung cancers occur within the first two years after resection.
Dib u soo noqoshada ayaa sabab muhiim u ah fashilka bukaano badan oo kansarka sanbabada ah inay la dagaalamaan kansarka. Sida looga fogaado soo noqoshada qalliinka ka dib waa mawduuc welwel ku leh bukaan kasta iyo qoys kasta.
Waa maxay soo noqoshada kansarku?
Dib u soo noqoshada kansarka waxaa lagu qeexaa sida ku soo noqoshada kansarka bukaanka kansarka la daweeyey ka dib in mudo ah ka dib markii laga bogsado ama aan la helin calaamadaha kansarka. Kansarrada laga helo saddex bilood gudahood laga soo bilaabo markii cudurka asalka ahaa guud ahaan waxaa loo tixgeliyaa horumarka kansarka. Cudurka kansarka 'metastasis' waxaa loola jeedaa ifafaalaha unugyada kansarka leh ay ka soo saaraan dhaawacyada aasaasiga ah ee sanbabada illaa xubnaha kale, oo ay ku koraan kuna sii bataan xubnaha.
Soo-noqoshada waxaa loo qaybin karaa saddex xaaladood iyadoo loo eegayo meelaha kala duwan ee soo noqnoqoshada:
1. Soo noqoshada maxalliga ah-nabarradii weli waxay ku jirtaa sambabada, oo ku xigta nabarradii asalka ahayd;
2. Regional recurrence-when the lesion recurs in the lymph nodes near the original buro;
3. Distal recurrence-when a lung cancer relapses in the bones, brain, adrenal glands or liver.
Maxay yihiin sababaha soo noqnoqda kansarka sanbabada?
Fursadda kansarka sanbabada ee soo noqnoqda waxay kuxirantahay arrimo badan, oo ay kujiraan nooca kansarka sanbabada, marxalada kansarka sanbabada markii la ogaado, iyo daaweynta kansarka asalka ah.
After the diagnosis of lung cancer, the first treatments play an important role, such as surgery and radiotherapy, which are considered local treatments, which can treat cancers that exist around the original tumor site. Sometimes the cells in the original tumor spread farther through the bloodstream or lymphatic channels, but these cells are too small to be detected by imaging. Chemotherapy is a systemic treatment that mainly treats cancer cells that may be present throughout the body. Unfortunately, chemotherapy has large side effects and is prone to drug resistance. Even with chemotherapy, cancer cells may survive and continue to grow in the future.
Maxay yihiin astaamaha kansarka sanbabada soo noqnoqda?
Calaamadaha kansarka sanbabada ee soo noqnoqda waxay kuxirantahay halka kansarku ku soo laabto. Haddii ay tahay soo noqnoqoshada maxalliga ah, ama qanjidhada qanjidhada ee u dhow burooyinka asalka ah, astaamaha waxaa ka mid noqon kara qufac, hemoptisis, neef qabad, xiiq, ama oof-wareen. Soo noqoshada maskaxda waxay sababi kartaa dawakhaad, araga oo hoos u dhaca ama aragtida labalaabma, daciifnimo ama luminta wadashaqeynta dhinac jirka ah. Ku soo noqoshada beerka waxay sababi kartaa calool xanuun, cagaarshow (maqaarka oo huruud noqda huruud), cuncun ama jahwareer. Dib u soo noqoshada lafuhu waxay badanaa ku badan tahay xanuun qoto dheer oo ku dhaca laabta, dhabarka, garbaha, ama addimada. Calaamadaha caanka ah ee badan sida daalka iyo miisaanka oo si lama filaan ah u lumiya sidoo kale waxay noqon karaan kuwo saadaal u ah soo noqoshada kansarka.
Sidee looga hortagaa soo noqoshada kansarka sanbabada?
Dib u eegis xilliyeed
Maadaama kansarka sanbabku uusan lahayn calaamado la isku halleyn karo oo horay loo sii saadaaliyay oo ku saabsan soo noqoshada iyo metastasis, si loo ogaado soo noqoshada ama metastasis goor hore, kormeer dhow iyo la socoshada cudurka ayaa loo baahan yahay.
Guud ahaan marka laga hadlayo, sanadka ugu horeeya ee hawlgalka dib u eegis ayaa lagu sameeyaa seddexdii biloodba mar; sanadka labaad, qalliinka waa lagu celceliyaa lixdii biloodba mar, waxaana la sii wadaa baaritaanka meertada ah.
Strictly follow the doctor’s advice and review regularly and on time. When the patient has symptoms, a corresponding chest and abdomen CT, craniocerebral CT or MRI, bone scan, fiberoptic bronchoscopy, etc. should be performed.
Daaweynta ka dib, bukaanada qaba kansarka sanbabada waxaa ku dhici kara dhibaatooyin ama astaamo kale xaaladooda iyo sababo kale awgood. Sidaa darteed, dib-u-eegista joogtada ah waa inaan la iska indhatirin oo waa in fiiro gaar ah la siiyaa.
Ogaanshaha Biomarker
An important tool for predicting the risk of recurrence is the use of molecular biology techniques. Lung cancer is a highly invasive tumor. Pathological classification (histological differentiation, vascular infiltration, lymphatic infiltration, and pleural infiltration), tumor TNM stage, and genotyping are all closely related to prognosis. Genetic testing and immunohistochemistry can be combined to use genetic mutations, such as KRAS status, and CEA and Ki-67 expression levels to predict risk of recurrence.
In la xoojiyo nafaqada lagana hortago hargabka
Bukaannada qaba kansarka sanbabada, nafaqada waa in loo damaanad qaadaa si looga fogaado hargabka, waana in fiiro gaar ah la siiyaa cuntada. Xulashada cuntada waa inay ahaato mid hodan ah oo kaladuwan, oo leh miraha iyo khudradda darayga ah. Bukaannada waayeelka ah, cunista boorash badan iyo cuntooyin maraq ah ayaa si fiican u dheefshiidi doona. Isla mar ahaantaana, waa inaan fiiro gaar ah u yeelano dammaanad qaadka nafaqada iyo qaadashada borotiinka oo tayo sare leh.
Bukaanka qaba kansarka sanbabada waa inay fiiro gaar ah u yeeshaan diirimaadka, ka hortagga hargabka iyo ka fogaanshaha cudurka. Hadday tahay infekshan fayras ama bakteeriya, waxay sababi doontaa in difaaca jirka uu hoos u dhaco, waana u fududahay unugyada kansarku inay tarmaan oo ay dib u soo laabtaan.
Hagaaji noloshaada oo sii joog farxad
Quit alcohol, quit alcohol, quit alcohol, important things are said three times, you must quit alcohol. In addition, don’t smoke, don’t overwork, pay attention to emotional regulation, and maintain a happy mood.
Jimicsi ku habboon, 2-3 bilood qalliinka ka dib, waxaad samayn kartaa jimicsi dabacsan, sida socodka, oo si tartiib tartiib ah u kordhi 15 daqiiqo ilaa 40 daqiiqo; Waxa kale oo aad jimicsan kartaa qigong, Tai Chi, jimicsi raadiyaha iyo jimicsiyo kale oo dabacsan.
Feejignaan gaar ah waa in la siiyaa cuntada, ha cunin cunno caaryo ah, hilib dubis, hilib doofaar, tofu iyo cuntooyinka kale ee ay ku jirto nitrite, hana cunin dawooyinka dhaqameed ee Shiinaha.
Daaweynta kansarka sanbabada
Qalliinka
Sida ugu wanaagsan ee lagu daaweyn karo kansarka sanbabada waa in laga saaro dhaawacyada soo noqnoqda si loo gaaro hadafka daaweynta xagjirka ah. Haddii shuruudaha qalliinka la buuxiyo, burooyinka oo dhan ayaa qalliin looga saari karaa.
Haddii ay jiraan nabaro kala duwan, aagga duulaanka ayaa ah mid aad u ballaaran, ama metastases fog, dib-u-soo-baxa burooyinka ayaa loo dooran karaa iyadoo loo eegayo xaaladda. Xaaladda ah in faa'iidada qalliinka aan la damaanad qaadi karin, hababka kale ee daaweynta ayaa la dooran karaa.
Daaweynta Proton ee daaweynta kansarka sanbabada
Radiotherapy is an adjuvant treatment for many patients with postoperative lung cancer. However, in traditional radiotherapy, X-rays or photon beams are inevitably transmitted to the tumor site and the surrounding healthy tissues. This can damage nearby healthy tissue and can cause serious side effects. Proton daawaynta waxay si fiican uga fogaan kartaa dhibaatooyinkaas soo raaca.
In contrast, proton therapy uses proton beam irradiation and can stop at the tumor site without leaving a radiation dose behind the tumor, so it is unlikely to damage nearby healthy tissue. Some experts believe that proton therapy is safer than traditional radiation therapy.
Bukaannada kansarku waxay leeyihiin difaac hooseeya, soo-gaadhista shucaaca ee xoogga leh waxay si fudud u sababi kartaa waxyeello u geysata xubnaha caadiga ah, waxay u keentaa fal-celinno xun oo daran, waxayna culeys culus u keentaa jirka oo markii horaba daciif ahaa. Gaar ahaan kansarka sanbabada, nabarrada burooyinka waxay ku xigaan xubno fara badan oo muhiim ah, sida beerka, wadnaha, hunguriga, iwm, iyo sidoo kale metastases-ka maskaxda ku dhaca ee kansarka sanbabada ku dhaca. Doorashada daaweynta proton waxay si wax ku ool ah uga fogaan kartaa waxyeellada unugyada caafimaadka qaba ee ku hareeraysan waxayna ku guuleystaan isla saameynta dilka sida shucaaca caadiga ah.
Daaweynta Dawada Kansarka Sambabka
Daaweynta Targeted
With the continuous advancement of precision medicine and the continuous advent of various targeted drugs, the front-line treatment of kansarka sanbabada ee aan yareyn (NSCLC) has changed from chemotherapy to the preferred targeted treatment.
These six key driver gene mutations in non-small cell lung cancer targeted drugs: EGFR (exon 19/21), ALK, BRAF V600E, ROS1, RET, and NTRK are important for patients with lung cancer because they already have Very effective targeted drugs can be used for treatment, replacing traditional chemotherapy.
Cudurka kansarka sanbabada ee isbeddelka 'EGFR':
Xulashada daawooyinka daaweynta koowaad: gefitinib, erlotinib, afatinib, dacotinib, ositinib, iyo ectinib (daroogada guryaha).
Fursadaha daaweynta dabagalka: Oxitinib.
ALK kansarka sanbabada dib-u-habayn-wanaagsan
Fursadaha daaweynta safka hore: crizotinib, ceritinib, aletinib, iyo bugatinib.
Daaweynta la-socoshada: Aletinib, Bugatinib, Ceritinib, Lauratinib.
ROS1 dib u habeyn-kansarka sanbabada oo wanaagsan:
Xulashada daroogada koowaad: ceritinib, crizotinib, emtricinib.
BRAF V600E isbeddel-kansarka sanbabada
Fursadaha daaweynta safka hore: Dalafenib + Trametinib
Daaweynta la-socoshada: Dalafenib + Trametinib
NTRK hiddo-wadaha kansarka sanbabada oo wanaagsan:
Fursadaha daaweynta safka koowaad: Larotinib, Emtricinib.
Daaweynta la-socoshada: Larotinib, Emtricinib.
Ma jiraan bartilmaameedyo badan oo isku -beddel ah oo kansarka sanbabadu ogaan karo? Dabcan maya. Intaa waxaa dheer, waxaa jira isbeddello bartilmaameedyo soo baxaya sida MET, RET, HER2, iwm. immunotherapy. Haddii la ogaado isbeddeladan bartilmaameedka ah ee soo ifbaxaya, waxaad dooran kartaa daaweynta daweynta ee u dhiganta (eeg jadwalka hoose)).
Bartilmaameedyada hiddo-wadaha ee soo ifbaxaya iyo daroogooyinka lagu bartilmaameedsado kansarka sanbabada ee unugyada aan yareyn
| Bartilmaameedka isbeddelka | Dawooyinka la bartilmaameedsado ee la heli karo |
| Kordhinta MET ama ka-beddelid 14 isbeddel ah | Crizotinib (NCCN); Capmatinib, Tepotinib (ASCO) |
| Dib u habeyn RET | Cabozantinib, Vandetanib (NCCN); LOXO292, BLU667 (ASCO) |
| HER2 (ERBB2) isbeddel | Isku-duwaha Trastuzumab-Metasin (NCCN) |
| TMB (culeyska isbeddelka burooyinka) | Nivolumab + Ipilimumab, Nivolumab (NCCN)
|
Xulashada daroogada ee kansarka sanbabada marka uusan jirin isbeddel hidde ah
For patients with non-small cell lung cancer without genetic mutations, an important biomarker still needs to be detected, that is PD-L1. PD-L1 is up-regulated in many tumor cells. 1 combination, can inhibit the proliferation and activation of T cells, make T cells in an inactive state, and finally induce immune escape, tumorigenesis and development.
Habka ogaanshaha baaritaanka ee loo yaqaan 'FDA-ansixiyay' PD-L1 weheliyaha wuxuu hagi karaa paimumab daaweynta bukaannada NSCLC, iyadoo lagu saleynayo dhibcaha saamiga burooyinka (TPS). TPS waa boqolleyda unugyada burooyinka wax-qabadka leh oo muujinaya midab-xuub qayb ahaan ama buuxa xinjir kasta oo xoog leh.
Kansarka sanbabada ee aan-yareyn oo leh muujinta PD-L1 ee TPS ≥1%
Fursadaha daaweynta koowaad:
Daaweynta daaweynta Paimumab
2. Kansarka unugyada aan-xajmiga lahayn: (karboplatin / cisplatin) + pemetrexed + paimumab
3. Non-squamous cell carcinoma: carboplatin + paclitaxel + bevacizumab + atejuzumab
4.Carcinoma cell-ka: (karboplatin / cisplatin) + (paclitaxel / albumin paclitaxel) + paimumab
Haddii labada isbadal ee hiddo-wadaha la ogaado oo muujinta PD-L1 kor loo qaado, daaweynta daroogada ee la bartilmaameedsaday ayaa la door bidaa.
Xulashada daroogada koowaad ee kansarka sanbabada ee unugyada yar-yar (ma laha isbadal hidde ah, ma laha iska caabbinta difaaca jirka, Dhibcaha PD 0-1)
| PD-L1 TPS (dhibcaha saamiga burooyinka) | Fursadaha daawada-koowaad | Heerka caddaynta | Xoog lagu taliyay |
| ≥50% | K daroogada hal daroogada ah | sare | Strong |
| ≥50% | K daroogada + karboplatin + paclitaxel ama albumin paclitaxel | in | Strong |
| ≥50% | Ma jirto caddayn kale oo ah ka-hortagayaasha isbaaradayaasha difaaca jirka oo ay weheliso kiimiko-daaweyn safka-koowaad ah | sare | Strong |
| 0,1-49% | K daroogada + karboplatin + paclitaxel ama albumin paclitaxel | in | Strong |
| 0,1-49% | Kahortaga difaaca jirka, daaweyn ka kooban platinum ayaa suuragal ah | sare | Strong |
| 0,1-49% | Kahortaga difaaca jirka, kuma haboona daaweynta ciribtirka, non-platinum chemotherapy laba-wakiil ayaa la dooran karaa | in | tabar daran |
| 0,1-49% | Diido daroogada K ee isku jirta kemotherabi, laakiin daroogada K daroogada hal | hooseeyo | tabar daran |
Faallooyin: daroogada K waa paimumab, daawada T waa atezumab, labada daawooyinba waxaa lagu suuq geeyay Shiinaha
Xulashada dawada safka hore ee n
kansarka sanbabada ee unugyada yar (ma laha isbadal hidde ah, ma laha iska caabbinta difaaca jirka, dhibcaha PD 0-1)
| PD-L1 TPS (dhibcaha saamiga burooyinka) | Fursadaha daawada-koowaad | Heerka caddaynta | Xoog lagu taliyay |
| ≥50% | K daroogada hal daroogada ah | sare | Strong |
| ≥50% | K daroogada + karboplatin + pemetrexed | sare | Strong |
| ≥50% | K daroogada + karboplatin + paclitaxel + bevacizumab | in | in |
| ≥50% | T daroogada + karboplatin + albumin paclitaxel | hooseeyo | tabar daran |
| ≥50% | Ma jirto caddayn kale oo ah ka-hortagayaasha isbaaradayaasha difaaca jirka oo ay weheliso kiimiko-daaweyn safka-koowaad ah | sare | Strong |
| 0,1-49% | K daroogada + karboplatin + pemetrexed | sare | Strong |
| 0,1-49% | T ilaa + karboplatin + paclitaxel + bevacizumab | in | in |
| 0,1-49% | K daroogada + karboplatin + albumin paclitaxel | in | in |
| 0,1-49% | Diido tallaalka, daawada kiimiko ah ee ay ku jiraan daawada loo yaqaan 'platinum' | sare | Strong |
| 0,1-49% | Kahortaga difaaca jirka, kuma haboona daawada ay kujirto platina, daawada aan dawada lahayn ee dawada aan dawada lahayn waa ikhtiyaari | in | tabar daran |
| 0,1-49% | Diido daroogada K ee isku jirta kemotherabi, laakiin daroogada K daroogada hal | hooseeyo | tabar daran |
Faallooyin: daroogada K waa paimumab, daawada T waa atezumab, labada daawooyinba waa laga suuq geeyay Hindiya.
Tallaalka kansarka sanbabka
Sannadkii 2008, Cimavax-EGF, oo ah tallaalkii ugu horreeyay ee borotiinka-peptide ee daaweynta marxaladda III iyo kansarka sanbabada, ayaa si guul leh loo soo saaray; - 2012, Cuba successfully developed the second lung cancer vaccine, Vaxira.
Tallaalka peptide ee borotiinka ah ee suuqgeynta adduunka ugu horreeya-Cimavax-EGF
Tilmaam: IIIB, IV kansarka sanbabada ee unugyada aan yareyn.
Waqtiga suuqa: 2011 (ku qoran Cuba)
Kadib 25 sano oo cilmi baaris ah, Kuuban cilmi baarayaashu waxay ku guuleysteen diyaarinta tallaal joojin kara horumarka kansarka sanbabada.
Xogta Tijaabada:
CIMAvax-EGF ee bukaanada qaba NSCLC horumarsan (Wajiga III kiliinikada tijaabada ah) waxay cadeyneysaa in talaalku amaan yahay oo wax ku ool u yahay bukaanada qaba NSCLC horumarsan.
Tijaabada wajiga III, heerka noolaanshaha 5-sano ee maadooyinka la talaalay wuxuu ahaa 14.4%, marka la barbardhigo kaliya 7.9% kooxda xakamaynta, ku dhowaad labalaab!
Ku habboon bukaanada:
Sambabka tallaalada kansarka are not effective in all patients. The most suitable population is: only for patients with advanced non-small cell lung cancer lung cancer, lung cancer patients with stable disease after first-line chemoradiation and no brain metastases If the patient is in advanced disease, the vaccine is not suitable.
Baarayaasha ayaa kalsooni ku qaba in shantii qofba mid ka mid ah bukaanadan uu guuleysan doono. Burooyinka badankood way baaba'een, bukaanada qaarna gabi ahaanba waa lawaayay! 23% bukaannada ayaa badbaaday in ka badan 5 sano. In kasta oo ay yihiin kansarka sanbabada, ka dib markay helaan daaweynta tallaalka, way shaqeyn karaan oo si caadi ah ayey u noolaan karaan, iyo tayada noloshooda oo aad u sarreysa, taasoo wax ku ool ah dib u dhigeysa horumarka cudurka.
Note, however, that CimaVax EGF cannot stop the development of cancer, let alone cure it. Instead, a mechanism was initiated, through which the uncontrolled growth and division of cancer cells was more restricted, thereby transforming advanced invasive lung cancer into a chronic disease. At present, the Cuban lung cancer vaccine has been approved in more than 80 countries around the world, and domestic patients can also apply to purchase the vaccine for treatment from Cuba adigoo soo wacaya + 91 96 1588 1588.
